TerminatedPhase 2

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Stopped: Sponsor Decision

United States73 participantsStarted 2025-01-02

Plain-language summary

The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects will receive IMP for 28 days followed by one End of Study (EOS) visit, 4 weeks after EOT visit.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Any infection requiring systemic treatment within 14 days prior to baseline.
✕. A history of opportunistic, recurrent, or chronic infections that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.

What they're measuring

Frequency, severity, and relatedness of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

Timeframe: Through study completion, an average of 10 weeks

Trial details

NCT IDNCT06555328

SponsorInflaRx GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01-22

View on ClinicalTrials.gov More Chronic Urticaria, Idiopathic trials